Goodbody Health Inc. - Extension of scope of ISO 17025
RNS Number : 8101A
Goodbody Health Inc.
07 February 2022

 7 February 2022

Goodbody Health Inc.
("Goodbody Health Group", or the "Company")


Extension of scope of ISO 17025

Goodbody Health Group receives extension of scope of ISO 17025 to meet Government Chemist and ACMD Guidance.


Goodbody Health Inc is pleased to announce its subsidiary Phytovista Laboratories has achieved another significant milestone with an extension to its ISO 17025 UKAS accreditation with a test to meet Government Chemist and the Advisory Council on the Misuse of Drugs ("ACMD") Guidance, one of a very small number of laboratories accredited for this type of testing.


As identified in the 2021 Government Chemist CBD Food and Cosmetic Ring Trial report, and others, advanced testing methodology is desirable to give the required sensitivity and selectivity to reliably detect traces of residues of controlled cannabinoids in consumer CBD products.


PhytoVista laboratories is now ideally positioned to help CBD companies achieve compliance by providing data in accordance with the ACMD guidance on acceptable levels of controlled cannabinoids in consumer products.


The Government Chemist has been recognised for their contribution in advising government and contributing to the ACMD, enabling the UK to lead the way in creating a fully regulated Novel Food consumer CBD market, facilitating consumer choice and confidence.


Geremy Thomas, Executive Chairman, said; "This is another example to show how we as a group not only lead the way in supplying the best quality products but also continue to support the whole CBD industry to put quality and compliance first."


For further information:

Marc Howells

Chief Executive Officer

Goodbody Health Inc.

+44 (0) 20 7971 1255

Anne Tew

Chief Financial Officer

Goodbody Health Inc.

+44 (0) 20 7971 1255



AQSE Corporate Adviser

Arden Partners plc

Antonio Bossi / George Morgan

+ 44 (0) 20 7614 5900 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.